Use of 1C specific compounds to treat benign prostatic hyperlasia
Patent 5403847 Issued on April 4, 1995. Estimated Expiration Date: 
November 13, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
November 13, 2012. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesOptically-active 1,4-dihydropyridine 1,4-dihydropyridine enantiomers Patent #: 4994461 InventorsAssigneeApplicationNo. 975867 filed on 11/13/1992US Classes:514/318, The additional ring is a six-membered hetero ring consisting of one nitrogen and five carbon atoms514/654The chain consists of two or more carbons which are unsubtituted or have acyclic hydrocarbyl substituents onlyExaminersPrimary: Henley, III, RaymondAssistant: Jarvis, William R. A. Attorney, Agent or FirmForeign Patent References
International ClassesA61K 031/445A61K 031/135 AbstractA method of treating benign prostatic hyperplasia in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to a human adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human adrenergic receptor, a human adrenergic receptor, and a human histamine H1 receptor, and, binds to a human 댒 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such adrenergic receptor. Compounds meeting these criteria are provided.Other References
| |
